Conceived and designed the experiments: CW YHZ YTD. Performed the experiments: RH JJC QJC CCX YL. Analyzed the data: RH YHZ. Contributed reagents/materials/analysis tools: QG BZ JW KZ JQL. Wrote the paper: YHZ.
Novel avian influenza A(H7N9) virus was isolated in fatal patients in Yangtze River Delta of China in March 2013. We aimed to screen the virus in febrile patients in a tertiary hospital in an area with confirmed cases. Throat-swab specimens collected from consecutive patients with fever (≥38°C) and flu-like symptoms from April 15 to April 25, 2013 were subjected to detect novel avian influenza A(H7N9) virus with real-time PCR. The clinical outcomes in the patients and close contacts were followed up. Of total 200 patients screened, one (0.5%) was positive for avian influenza A(H7N9) virus and 199 others were negative. The infected patient experienced respiratory failure and had diffuse infiltrates in the right lower lobe in chest CT images. He received symptomatic and antibacterial treatments as well as oseltamivir. His condition was substantially improved within three days after admission; avian influenza A(H7N9) virus was not detected after 5 days' antiviral therapy. The hemagglutinin inhibition test showed that the serum titers against avian influenza A(H7N9) virus increased from <1∶20 at the early phase to 1∶80 at the convalescent phase. Follow-up of 23 close contacts showed that none of them developed fever and other symptoms within two weeks. Our findings suggest that although the infection rate of avian influenza A(H7N9) virus in patients with fever and flu-like symptoms is rare, the screening is valuable to rapidly define the infection, which will be critical to improve the clinical outcomes.
During March 2013, a novel influenza virus of avian origin, influenza A(H7N9), was isolated from three patients with fatal severe respiratory disease in Shanghai and Anhui, both located in the Yangtze River Delta Region, east part of China
According to the diagnostic criteria, a suspected case of avian influenza A(H7N9) is defined when a patient has fever, respiratory symptoms such as sore throat or cough, toxemia symptoms such as headache, malaise, or myalgia, and supportive epidemiologic evidence such as contact with poultries and living at areas where confirmed case was reported
Nanjing Drum Tower Hospital is a 2,400-bed tertiary medical center with 35 departments, including an emergency department with the fever clinic and an independent intensive care unit (ICU) with 51 beds and 6 isolation rooms. During late March and early April 2013, five patients who attended to our hospital were confirmed to have caught avian influenza A(H7N9)
Written informed consent was obtained from all patients involved in this study. The study was approved by the Ethics Committee of Nanjing Drum Tower Hospital (EC20130411-1).
During the late March and the early April 2013, several patients with high fever and server pneumonia were admitted to our hospital. On April 2, two of them were confirmed to be infected with avian influenza A(H7N9) virus by the Chinese Center for Disease Control and Prevention in Beijing; one more patient was confirmed the infection by the Jiangsu Provincial Center for Disease Control and Prevention in Nanjing on April 4
Each swab was vigorously shaken in 0.5 mL of diethylpyrocarbonate treated water and squeezed on the inside surface of tube to release as much trapped virus as possible before the swab was taken out. Each of the samples was added with 1.0 mL TRIzol (Invitrogen, Life Technologies, USA), vortexed for at least 15 s, and then stored at −70°C.
The total RNA was extracted from samples in TRIzol according to the manufacturer's instructions. To increase the recovery rate of RNA, we added 0.5 µL glycogen (20 mg/mL) in the precipitation of RNA. The final pellet was dissolved in 10 µL diethylpyrocarbonate treated water. Five microliters each was used to detect H7 and N9 genes respectively with the fluorescence reverse transcription (RT) PCR Detection kits (BioPerfectus Technologies, Taizhou, Jiangsu Province, China) on ABI 7500 Real time PCR system (Applied Biosystems). The protocols and primers were prepared in accordance with those provided the WHO Collaborating Centre in Beijing
The virus isolation was performed essentially as described previously
The hemagglutinin inhibition (HAI) assay was performed with 0.5% chicken red blood cells as described elsewhere
Statistical analysis was performed using SPSS software version 13.0 (SPSS, Chicago, USA). We summarized the continuous variables as means and standard deviation. For categorical variables, the percentages of patients in each category were calculated.
From April 15 to April 25, 2013, totally 5,009 patients attended to the outpatient emergency department of our hospital. Of them, 337 with fever ≥38°C were required to attend the fever clinic of our hospital. A total of 200 febrile patients, who also presented flu-like symptoms, were recruited in this study to have their throat-swab specimens tested for the presence of avian influenza A(H7N9) virus with fluorescence RT-PCR. Their general characteristics and results of routine blood tests are shown in
| Variable | Value |
| Age, years | 34.13±14.88 |
| Gender | |
| Male | 110 (55.0) |
| Female | 90 (45.0) |
| Symptoms | |
| Fever | 200 (100.0) |
| Temperature, °C | 38.72±0.56 |
| Sore throat | 149 (74.5) |
| Cough | 95 (47.5) |
| Myalgia | 90 (45.0) |
| Malaise | 10 (5.0) |
| Headache | 89 (44.5) |
| Routine blood testing | |
| Leukocyte count, ×109/L | 10.18±4.14 |
| <4×109/L | 5 (2.5) |
| >10×109/L | 93 (46.5) |
| Lymphocyte count, ×109/L | 1.43±1.01 |
| Neutrophil, ×109/L | 7.93±3.91 |
| Hemoglobin, g/L | 140.10±17.73 |
| Platelet count, ×109/L | 180.25±46.37 |
%) or mean ± standard deviation. Values are no. patients (
One (0.5%) of the 200 patients showed positive in the tests of both avian influenza virus H7 and N9 in RT-PCR and 199 others (99.5%) were negative. Additional throat-swab specimens from the patient with positive avian influenza A(H7N9) virus RNA, which had been collected the next day, were retested with the same kit in two other independent laboratories; both laboratories reported positive. Thus the patient was diagnosed with the infection of avian influenza A(H7N9) virus. All other patients were excluded from the infection of the virus, and recovered after 1–3 weeks treatment.
The patient diagnosed with the infection of avian influenza A(H7N9) virus was a 36-year-old man who lived in Xinyi city, which is located in north part of Jiangsu Province, 310 km away from Nanjing. He was a living poultry retailer and had transported living poultry from Xinyi city to Hangzhou city, the capital of Zhejiang Province, where sporadic avian influenza A(H7N9) occurred from February to April, 2013
On the physical examination in our hospital, the patient had high fever (40.2°C), dyspnea and lip cyanosis. Blood tests revealed that leukocytes were 3.3×109/L with neutrophils of 2.6×109/L, lymphocytes of 0.5×109/L, platelet of 93×109/L, and red blood cells 4.38×1012/L, and the liver and kidney functions were generally normal. The sputum cultures for bacteria in the first three days were all negative. Arterial blood gas analysis presented the results of pH 7.441, PO2 64 mmHg, PCO2 30.5 mmHg, and SaO2 93%, under nose tubular oxygen supplement (5 L/min). Chest x-ray and computed tomographic (CT) scanning revealed consolidation and diffuse infiltrates in the right lower lobe and patchy infiltrates in the left lower lobe (
(A and B) Chest radiographs taken 5 and 25 days respectively after the onset of symptoms. Diffuse infiltrates and consolidation may be observed in the right lower lobe on day 5 (A) and the infiltrates are largely disappeared on day 25 (B). (C to F) Chest CT scans during the illness course and follow-up. The scanning was performed on day 4 (C), 21 (D), 43 (E), and 75 (F) respectively after the onset of symptoms.
Once the diagnosis was established on April 24, the patient was quarantined in the isolation room to prevent the potential transmission and treated with the combination therapy against influenza A, including oseltamivir and piperacillin/tazobactam (Tazocin). The main clinical features, laboratory findings, and treatment during the disease course are presented in
HAI, titers of hemagglutinin inhibition against the novel avian influenza A(H7N9) virus.
The hemagglutinin inhibition test showed that the serum at the early phase of the illness, on day 6 after the onset, had the titers lower than 1∶20 against avian influenza A H7N9, H5N1, and 2009H1N1, respectively, but had a titer of 1∶80 against seasonal influenza A H1N1. However, the serum of convalescent phase, on day 44 after the onset, had titers of 1∶80 against avian influenza A(H7N9) virus (
| Serum | ||
| Virus isolate | Acute phase | Convalescent phase |
| A/Shanghai/2/2013 (H7N9) | <20 | 80 |
| A/Anhui/1/2013 (H7N9) | <20 | 80 |
| A/Chicken/Hunan/246/2012 (H5N1) | <20 | <20 |
| A/California/07/2009 (H1N1) | <20 | 20 |
| A/New Caledonia/20/99 (H1N1) | 80 | 80 |
The patient had not been quarantined until his diagnosis was established on April 24, 2013. Some persons closely contacted the patient without strict preventive measures. These included his parents, his wife and two children, and 18 physicians and nurses. We followed these persons to investigate whether avian influenza A(H7N9) virus was transmitted from human to human. None of the 23 close contacts developed the fever and flu-like symptoms within 14 days after contact.
In the present study, we investigated the novel avian influenza A(H7N9) virus in the patients with fever and flu-like symptoms in an area with confirmed cases during the onset season. Of the 200 patients investigated, one (0.5%) was defined with infection of the virus, indicating that, even in areas with the confirmed cases during the onset season, the infection rate of avian influenza A(H7N9) virus in the flu-like patients is low. However, the incidence is higher than that (0.03%) in 20,739 patients with influenza-like illness from 10 provinces with confirmed human cases
In this investigation, no patient with fever and flu-like symptoms who attended to the Emergency Department of our hospital during the screening period refused to participate, indicating that no patient infected with avian influenza A(H7N9) virus was neglected. Furthermore, the screening method, developed according to the protocols of the WHO Collaborating Centre in Beijing
Since avian influenza A(H7N9) virus causes fatal disease in human, one of main concerns on this disease is the issue of whether the virus is prone to human-to-human transmission. In the present study, we traced the close contacts who had not taken the precautionary measures, and none of them developed flu-like symptoms. The results imply that the human-to-human transmission of the avian influenza A(H7N9) virus appears to be rare, although it is reported that the virus can bind to human-type α2,6-linked sialic acid receptors, and infect epithelial cells derived from the human lower respiratory tract and type II pneumonocytes derived from the human alveoli
It is interesting to note that the patient infected with avian influenza A(H7N9) virus found in this screening had experienced the disease not as severe as most of the other reported patients
In summary, although the infection rate of avian influenza A(H7N9) virus in an area with confirmed cases during the disease season is rare, the screening in patients with fever and flu-like symptoms is valuable to rapidly diagnose the patients in areas with confirmed cases during certain period of time, which will be critical to improve the disease outcomes and prevent the potential spread of avian influenza A(H7N9) virus.
We thank all participants for their cooperation and data collection.